BLC
HALO icon

Brown, Lisle/Cummings’s Halozyme HALO Stock Holding History

Brown, Lisle/Cummings’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3K Sell
285
-92
-24% -$6.27K 0.01% 490
2026
Q1 		$24.4K Buy
+377
New +$26.6K 0.01% 445

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Brown, Lisle/Cummings's HALO Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Halozyme (HALO) stake by 24% in Q2 2026, selling an estimated $6.27K and leaving 285 shares worth $22.3K. The position accounts for 0.01% of the portfolio, ranked #490.

Brown, Lisle/Cummings first reported a position in HALO in Q1 2026 and has held it in 2 quarters since. The position peaked at $24.4K in Q1 2026. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Brown, Lisle/Cummings held 285 shares of Halozyme worth $22.3K as of Q2 2026.
  • Brown, Lisle/Cummings sold 92 Halozyme shares in Q2 2026, an estimated $6.27K.
  • Halozyme made up 0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #490 holding.
  • Brown, Lisle/Cummings first reported a position in Halozyme in Q1 2026 and has held it in 2 quarters since.
  • Brown, Lisle/Cummings's Halozyme position peaked at $24.4K in Q1 2026.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.